Protein aggregation-inhibition: a therapeutic route from Parkinson’s disease to sickle cell anemia

References

• Abbott A. 2010. Levodopa: the story so far. Nature. 466(7310):S6–S7.
   PubMed Web of Science ®Google Scholar
• Abdulmalik O, Ghatge MS, Musayev FN, Parikh A, Chen Q, Yang J, Nnamani I, Danso-Danquah R, Eseonu DN, Asakura T, et al. 2011. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Acta Crystallogr D Biol Crystallogr. 67(Pt 11):920–928.
   PubMedGoogle Scholar
• Abdulmalik O, Safo MK, Chen Q, Yang J, Brugnara C, Ohene-Frempong K, Abraham DJ, Asakura T. 2005. 5-Hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 128(4):552–561.
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Kennedy PE, Mehanna AS, Patwa DC, Williams FL. 1984. Design, synthesis, and testing of potential antisickling agents. 4. Structure–activity relationships of benzyloxy and phenoxy acids. J Med Chem. 27(8):967–978.
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Perutz MF, Phillips SE. 1983. Physiological and X-ray studies of potential antisickling agents. Proc Natl Acad Sci U S A. 80(2):324–328.
   PubMed Web of Science ®Google Scholar
• Adachi K, Asakura T. 1978. Demonstration of a delay time during aggregation of diluted solutions of deoxyhemoglobin S and hemoglobin CHarlem in concentrated phosphate buffer. J Biol Chem. 253(19):6641–6643.
   PubMed Web of Science ®Google Scholar
• Adachi K, Asakura T. 1979. Nucleation-controlled aggregation of deoxyhemoglobin S. Possible difference in the size of nuclei in different phosphate concentrations. J Biol Chem. 254(16):7765–7771.
   PubMed Web of Science ®Google Scholar
• Adachi K, Asakura T. 1980. Polymerization of deoxyhemoglobin CHarlem (B6 Glu → Val, B73 Asp → Asn). J Mol Biol. 144(4):467–480.
   PubMed Web of Science ®Google Scholar
• Adachi K, Ding M, Wehrli S, Reddy KS, Surrey S, Horiuchi K. 2003. Effects of different B73 amino acids on formation of 14-stranded fibers of Hb S versus double-stranded crystals of Hb C-Harlem. Biochemistry. 42(15):4476–4484.
   PubMed Web of Science ®Google Scholar
• Adachi K, Konitzer P, Kim J, Welch N, Surrey S. 1993. Effects of beta 6 aromatic amino acids on polymerization and solubility of recombinant hemoglobins made in yeast. J Biol Chem. 268(29):21650–21656.
   PubMed Web of Science ®Google Scholar
• Afitska K, Fucikova A, Shvadchak VV, Yushchenko DA. 2017. Modification of C terminus provides new insights into the mechanism of α-synuclein aggregation. Biophys J. 113(10):2182–2191.
   PubMed Web of Science ®Google Scholar
• Aguzzi A, O’Connor T. 2010. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov. 9(3):237–248.
   PubMed Web of Science ®Google Scholar
• Ahmad B, Lapidus LJ. 2012. Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate. J Biol Chem. 287(12):9193–9199.
   PubMed Web of Science ®Google Scholar
• Akbar MGK, Tamura Y, Ding M, Ding H, Rosenblatt MM, Reddy KS, Surrey S, Adachi K. 2006. Inhibition of hemoglobin S polymerization in vitro by a novel 15-mer EF-helix β73 histidine-containing peptide. Biochemistry. 45(27):8358–8367.
   PubMed Web of Science ®Google Scholar
• Ameh SJ, Tarfa FD, Ebeshi BU. 2012. Traditional herbal management of sickle cell anemia: lessons from Nigeria. Anemia. 2012:607436.
   PubMedGoogle Scholar
• Arbo BD, André-Miral C, Nasre-Nasser RG, Schimith LE, Santos MG, Costa-Silva D, Muccillo-Baisch AL, Hort MA. 2020. Resveratrol derivatives as potential treatments for Alzheimer’s and Parkinson’s disease. Front Aging Neurosci. 12:103.
   PubMed Web of Science ®Google Scholar
• Armiento V, Spanopoulou A, Kapurniotu A. 2020. Peptide-based molecular strategies to interfere with protein misfolding, aggregation, and cell degeneration. Angew Chem Int Ed Engl. 59(9):3372–3384.
   PubMed Web of Science ®Google Scholar
• Arter WE, Xu CK, Castellana-Cruz M, Herling TW, Krainer G, Saar KL, Kumita JR, Dobson CM, Knowles TPJ. 2020. Rapid structural, kinetic, and immunochemical analysis of alpha-synuclein oligomers in solution. Nano Lett. 20(11):8163–8169.
   PubMed Web of Science ®Google Scholar
• Arya R, Rolan PE, Wootton R, Posner J, Bellingham AJ. 1996. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br J Haematol. 93(4):817–821.
   PubMed Web of Science ®Google Scholar
• Ashbaugh HS, Pratt LR. 2006. Colloquium: scaled particle theory and the length scales of hydrophobicity. Rev Mod Phys. 78(1):159–178.
   Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, et al. 2017. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 376(5):429–439.
   PubMed Web of Science ®Google Scholar
• Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. 1998. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol. 152(4):879–884.
   PubMed Web of Science ®Google Scholar
• Baell J, Walters MA. 2014. Chemistry: chemical con artists foil drug discovery. Nature. 513(7519):481–483.
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 53(7):2719–2740.
   PubMed Web of Science ®Google Scholar
• Baell JB, Nissink JWM. 2018. Seven year itch: pan-assay interference compounds (PAINS) in 2017—utility and limitations. ACS Chem Biol. 13(1):36–44.
   PubMed Web of Science ®Google Scholar
• Barone P. 2010. Neurotransmission in Parkinson’s disease: beyond dopamine: neurotransmission in Parkinson’s disease. Eur J Neurol. 17(3):364–376.
   PubMed Web of Science ®Google Scholar
• Bartolini M, Andrisano V. 2010. Strategies for the inhibition of protein aggregation in human diseases. Chembiochem. 11(8):1018–1035.
   PubMed Web of Science ®Google Scholar
• Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. 2017. Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 134(6):819–838.
   PubMed Web of Science ®Google Scholar
• Ben-Naim A. 1975. Hydrophobic interaction and structural changes in the solvent. Biopolymers. 14(7):1337–1355.
   Web of Science ®Google Scholar
• Ben-Naim A. 1978. A simple model for demonstrating the relation between solubility, hydrophobic interaction, and structural changes in the solvent. J Phys Chem. 82(8):874–885.
   Web of Science ®Google Scholar
• Berne BJ, Weeks JD, Zhou R. 2009. Dewetting and hydrophobic interaction in physical and biological systems. Annu Rev Phys Chem. 60(1):85–103.
   PubMedGoogle Scholar
• Bertoncini CW, Jung Y-S, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, Zweckstetter M. 2005. From the cover: release of long-range tertiary interactions potentiates aggregation of natively unstructured -synuclein. Proc Natl Acad Sci U S A. 102(5):1430–1435.
   PubMed Web of Science ®Google Scholar
• Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu G-M, Louis J-C, et al. 2000. Parkinson’s disease-associated α-synuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs. J Biol Chem. 275(44):34574–34579.
   PubMed Web of Science ®Google Scholar
• Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE. 2010. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A. 107(17):7710–7715.
   PubMed Web of Science ®Google Scholar
• Blair HA, Dhillon S. 2017. Safinamide: a review in Parkinson’s disease. CNS Drugs. 31(2):169–176.
   PubMed Web of Science ®Google Scholar
• Bodles AM, Guthrie DJS, Greer B, Irvine GB. 2001. Identification of the region of non-Aβ component (NAC) of Alzheimer’s disease amyloid responsible for its aggregation and toxicity: bioactive region of NAC. J Neurochem. 78(2):384–395.
   PubMed Web of Science ®Google Scholar
• Bookchin RM, Nagel RL, Ranney HM. 1967. Structure and properties of hemoglobin C-Harlem, a human hemoglobin variant with amino acid substitutions in 2 residues of the beta-polypeptide chain. J Biol Chem. 242(2):248–255.
   PubMed Web of Science ®Google Scholar
• Borah P, Sanjeev A, Mattaparthi VSK. 2021. Computational investigation on the effect of oleuropein aglycone on the α-synuclein aggregation. J Biomol Struct Dyn. 39(4):1259–1270.
   PubMed Web of Science ®Google Scholar
• Bosquesi PL, Melchior ACB, Pavan AR, Lanaro C, de Souza CM, Rusinova R, Chelucci RC, Barbieri KP, Fernandes GFDS, Carlos IZ, et al. 2020. Synthesis and evaluation of resveratrol derivatives as fetal hemoglobin inducers. Bioorg Chem. 100:103948.
   PubMed Web of Science ®Google Scholar
• Breydo L, Wu JW, Uversky VN. 2012. α-Synuclein misfolding and Parkinson’s disease. Biochim Biophys Acta. 1822(2):261–285.
   PubMed Web of Science ®Google Scholar
• Brugnara C. 2018. Sickle cell dehydration: pathophysiology and therapeutic applications. Clin Hemorheol Microcirc. 68(2–3):187–204.
   PubMed Web of Science ®Google Scholar
• Bu X-L, Rao PPN, Wang Y-J. 2016. Anti-amyloid aggregation activity of natural compounds: implications for Alzheimer’s drug discovery. Mol Neurobiol. 53(6):3565–3575.
   PubMed Web of Science ®Google Scholar
• Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416(6880):507–511.
   PubMed Web of Science ®Google Scholar
• Cao Z, Ferrone FA. 1997. Homogeneous nucleation in sickle hemoglobin: stochastic measurements with a parallel method. Biophys J. 72(1):343–352.
   PubMed Web of Science ®Google Scholar
• Carecho R, Figueira I, Terrasso AP, Godinho-Pereira J, de Oliveira Sequeira C, Pereira SA, Milenkovic D, Leist M, Brito C, Nunes dos Santos C. 2022. Circulating (poly)phenol metabolites: neuroprotection in a 3D cell model of Parkinson’s disease. Mol Nutr Food Res. 66(21):2100959.
   PubMed Web of Science ®Google Scholar
• Caruana M, Högen T, Levin J, Hillmer A, Giese A, Vassallo N. 2011. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 585(8):1113–1120.
   PubMed Web of Science ®Google Scholar
• Cascella R, Bigi A, Cremades N, Cecchi C. 2022. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. Cell Mol Life Sci. 79(3):174.
   PubMed Web of Science ®Google Scholar
• Castle BT, Odde DJ, Wood DK. 2019. Rapid and inefficient kinetics of sickle hemoglobin fiber growth. Sci Adv. 5(3):eaau1086.
   PubMed Web of Science ®Google Scholar
• Caughey B, Lansbury PT. 2003. Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 26(1):267–298.
   PubMedGoogle Scholar
• Cellmer T, Ferrone FA, Eaton WA. 2016. Universality of supersaturation in protein-fiber formation. Nat Struct Mol Biol. 23(5):459–461.
   PubMed Web of Science ®Google Scholar
• Chandler D. 2005. Interfaces and the driving force of hydrophobic assembly. Nature. 437(7059):640–647.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. 1995. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Uysal A, Stripe B, Ha Y, Marks TJ, Karapetrova EA, Dutta P. 2010. How water meets a very hydrophobic surface. Phys Rev Lett. 105(3):037803.
   PubMed Web of Science ®Google Scholar
• Chen K, Ballas SK, Hantgan RR, Kim-Shapiro DB. 2004. Aggregation of normal and sickle hemoglobin in high concentration phosphate buffer. Biophys J. 87(6):4113–4121.
   PubMed Web of Science ®Google Scholar
• Cheng F, Vivacqua G, Yu S. 2011. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J Chem Neuroanat. 42(4):242–248.
   PubMed Web of Science ®Google Scholar
• Cheruvara H, Allen-Baume VL, Kad NM, Mason JM. 2015. Intracellular screening of a peptide library to derive a potent peptide inhibitor of α-synuclein aggregation. J Biol Chem. 290(12):7426–7435.
   PubMed Web of Science ®Google Scholar
• Colizzi C. 2019. The protective effects of polyphenols on Alzheimer’s disease: a systematic review. Alzheimers Dement. 5(1):184–196.
   Web of Science ®Google Scholar
• Conti Nibali V, Pezzotti S, Sebastiani F, Galimberti DR, Schwaab G, Heyden M, Gaigeot M-P, Havenith M. 2020. Wrapping up hydrophobic hydration: locality matters. J Phys Chem Lett. 11(12):4809–4816.
   PubMed Web of Science ®Google Scholar
• Conway KA, Harper JD, Lansbury PT. 1998. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat Med. 4(11):1318–1320.
   PubMed Web of Science ®Google Scholar
• Conway KA, Rochet J-C, Bieganski RM, Lansbury PT. 2001. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science. 294(5545):1346–1349.
   PubMed Web of Science ®Google Scholar
• Cremades N, Chen SW, Dobson CM. 2017. Structural characteristics of α-synuclein oligomers. Int Rev Cell Mol Biol. 329:79–143.
   PubMed Web of Science ®Google Scholar
• Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, et al. 2012. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell. 149(5):1048–1059.
   PubMed Web of Science ®Google Scholar
• Cremades N, Dobson CM. 2018. The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases. Neurobiol Dis. 109(Pt B):178–190.
   PubMedGoogle Scholar
• Crowther RA, Jakes R, Spillantini MG, Goedert M. 1998. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 436(3):309–312.
   PubMed Web of Science ®Google Scholar
• Cunningham AD, Qvit N, Mochly-Rosen D. 2017. Peptides and peptidomimetics as regulators of protein–protein interactions. Curr Opin Struct Biol. 44:59–66.
   PubMed Web of Science ®Google Scholar
• Cyranoski D. 2017. Trials of embryonic stem cells to launch in China. Nature. 546(7656):15–16.
   PubMed Web of Science ®Google Scholar
• Dampier C. 2015. Orphan drugs for sickle vaso-occlusion: dawn of a new era of targeted treatment. Orphan Drugs Res Rev. 5:99.
   Google Scholar
• Das DR, Kumar D, Kumar P, Dash BP. 2020. Molecular docking and its application in search of antisickling agent from Carica papaya. J Appl Biol Biotechnol. 8(1):105–116.
   Google Scholar
• Dash B, Archana Y, Satapathy N, Naik S. 2013. Search for antisickling agents from plants. Pharmacogn Rev. 7(13):53–60.
   PubMedGoogle Scholar
• Davidson WS, Jonas A, Clayton DF, George JM. 1998. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 273(16):9443–9449.
   PubMed Web of Science ®Google Scholar
• Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90(3):537–548.
   PubMed Web of Science ®Google Scholar
• Davis JG, Gierszal KP, Wang P, Ben-Amotz D. 2012. Water structural transformation at molecular hydrophobic interfaces. Nature. 491(7425):582–585.
   PubMed Web of Science ®Google Scholar
• de Andrade Teles RB, Diniz TC, Costa Pinto TC, de Oliveira Júnior RG, Gama e Silva M, de Lavor ÉM, Fernandes AWC, de Oliveira AP, de Almeida Ribeiro FPR, da Silva AAM, et al. 2018. Flavonoids as therapeutic agents in Alzheimer’s and Parkinson’s diseases: a systematic review of preclinical evidences. Oxid Med Cell Longev. 2018:7043213.
   PubMed Web of Science ®Google Scholar
• Dean J, Schechter AN. 1978a. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches: (second of three parts). N Engl J Med. 299(15):804–811.
   PubMed Web of Science ®Google Scholar
• Dean J, Schechter AN. 1978b. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches: (third of three parts). N Engl J Med. 299(16):863–870.
   PubMed Web of Science ®Google Scholar
• Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM. 2005. Mapping long-range interactions in α-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc. 127(2):476–477.
   PubMed Web of Science ®Google Scholar
• Desai BS, Monahan AJ, Carvey PM, Hendey B. 2007. Blood–brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy. Cell Transplant. 16(3):285–299.
   PubMed Web of Science ®Google Scholar
• Dill KA. 1990. Dominant forces in protein folding. Biochemistry. 29(31):7133–7155.
   PubMed Web of Science ®Google Scholar
• Doherty CPA, Ulamec SM, Maya-Martinez R, Good SC, Makepeace J, Khan GN, van Oosten-Hawle P, Radford SE, Brockwell DJ. 2020. A short motif in the N-terminal region of α-synuclein is critical for both aggregation and function. Nat Struct Mol Biol. 27(3):249–259.
   PubMed Web of Science ®Google Scholar
• Doig AJ, Derreumaux P. 2015. Inhibition of protein aggregation and amyloid formation by small molecules. Curr Opin Struct Biol. 30:50–56.
   PubMed Web of Science ®Google Scholar
• Dong C, Garen CR, Mercier P, Petersen NO, Woodside MT. 2019. Characterizing the inhibition of α-synuclein oligomerization by a pharmacological chaperone that prevents prion formation by the protein PrP. Protein Sci. 28:1690–1702.
   PubMed Web of Science ®Google Scholar
• Dougherty PG, Qian Z, Pei D. 2017. Macrocycles as protein–protein interaction inhibitors. Biochem J. 474(7):1109–1125.
   PubMed Web of Science ®Google Scholar
• Du H-N, Tang L, Luo X-Y, Li H-T, Hu J, Zhou J-W, Hu H-Y. 2003. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry. 42(29):8870–8878.
   PubMed Web of Science ®Google Scholar
• Dykes G, Crepeau RH, Edelstein SJ. 1978. Three-dimensional reconstruction of the fibres of sickle cell haemoglobin. Nature. 272(5653):506–510.
   PubMed Web of Science ®Google Scholar
• Dykes GW, Crepeau RH, Edelstein SJ. 1979. Three-dimensional reconstruction of the 14-filament fibers of hemoglobin S. J Mol Biol. 130(4):451–472.
   PubMed Web of Science ®Google Scholar
• Eapen M, Brazauskas R, Walters MC, Bernaudin F, Bo-Subait K, Fitzhugh CD, Hankins JS, Kanter J, Meerpohl JJ, Bolaños-Meade J, et al. 2019. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 6(11):e585–e596.
   PubMed Web of Science ®Google Scholar
• Eaton WA, Bunn HF. 2017. Treating sickle cell disease by targeting HbS polymerization. Blood. 129(20):2719–2726.
   PubMed Web of Science ®Google Scholar
• Eaton WA, Hofrichter J. 1987. Hemoglobin S gelation and sickle cell disease. Blood. 70(5):1245–1266.
   PubMed Web of Science ®Google Scholar
• Eaton WA, Hofrichter J. 1990. Sickle cell hemoglobin polymerization. Adv Protein Chem. 40:63–279.
   PubMedGoogle Scholar
• Eaton WA. 2022. Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease. Mol Aspects Med. 84:100971.
   PubMed Web of Science ®Google Scholar
• Edelstein SJ. 1980. Structure of the fibers of hemoglobin S. Tex Rep Biol Med. 40:221–232.
   PubMedGoogle Scholar
• Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE. 2008. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 15(6):558–566.
   PubMed Web of Science ®Google Scholar
• El-Agnaf OMA, Jakes R, Curran MD, Wallace A. 1998. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson’s disease. FEBS Lett. 440(1–2):67–70.
   PubMed Web of Science ®Google Scholar
• El-Agnaf OMA, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, Fullwood NJ, Benson FE, Hewitt R, Ford KJ, et al. 2004. Strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson’s disease and related disorders. FASEB J. 18(11):1315–1317.
   PubMed Web of Science ®Google Scholar
• Elbaum D, Harrington JP, Bookchin RM, Nagel RL. 1978. Kinetics of Hb S gelation effect of alkylureas, ionic strength and other hemoglobins. Biochim Biophys Acta. 534(2):228–238.
   PubMedGoogle Scholar
• Elbaum D, Nagel RL, Bookchin RM, Herskovits TT. 1974. Effect of alkylureas on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A. 71(12):4718–4722.
   PubMed Web of Science ®Google Scholar
• Elbaum D, Roth EF, Neumann G, Jaffé ER, Bookchin RM, Nagel RL. 1976. Molecular and cellular effects of antisickling concentrations of alkylureas. Blood. 48(2):273–282.
   PubMed Web of Science ®Google Scholar
• Eliezer D, Kutluay E, Bussell R, Browne G. 2001. Conformational properties of α-synuclein in its free and lipid-associated states. J Mol Biol. 307(4):1061–1073.
   PubMed Web of Science ®Google Scholar
• El-Turk F, Newby FN, De Genst E, Guilliams T, Sprules T, Mittermaier A, Dobson CM, Vendruscolo M. 2016. Structural effects of two camelid nanobodies directed to distinct C-terminal epitopes on α-synuclein. Biochemistry. 55(22):3116–3122.
   PubMed Web of Science ®Google Scholar
• Errington JR, Debenedetti PG. 2001. Relationship between structural order and the anomalies of liquid water. Nature. 409(6818):318–321.
   PubMed Web of Science ®Google Scholar
• Esteban-Martín S, Silvestre-Ryan J, Bertoncini CW, Salvatella X. 2013. Identification of fibril-like tertiary contacts in soluble monomeric α-synuclein. Biophys J. 105(5):1192–1198.
   PubMed Web of Science ®Google Scholar
• Eugene C, Laghaei R, Mousseau N. 2014. Early oligomerization stages for the non-amyloid component of α-synuclein amyloid. J Chem Phys. 141(13):135103.
   PubMed Web of Science ®Google Scholar
• Fall AB, Vanhaelen-Fastré R, Vanhaelen M, Lo I, Toppet M, Ferster A, Fondu P. 1999. In vitro antisickling activity of a rearranged limonoid isolated from Khaya senegalensis. Planta Med. 65(3):209–212.
   PubMed Web of Science ®Google Scholar
• Farzadfard A, Pedersen JN, Meisl G, Somavarapu AK, Alam P, Goksøyr L, Nielsen MA, Sander AF, Knowles TPJ, Pedersen JS, et al. 2022. The C-terminal tail of α-synuclein protects against aggregate replication but is critical for oligomerization. Commun Biol. 5(1):123.
   PubMed Web of Science ®Google Scholar
• Feany MB, Bender WW. 2000. A Drosophila model of Parkinson’s disease. Nature. 404(6776):394–398.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Marguti I, Bechmann I, Jeney V, Chora Â, Palha NR, Rebelo S, Henri A, Beuzard Y, Soares MP. 2011. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell. 145(3):398–409.
   PubMed Web of Science ®Google Scholar
• Ferrone FA, Hofrichter J, Eaton WA. 1985a. Kinetics of sickle hemoglobin polymerization. I. Studies using temperature-jump and laser photolysis techniques. J Mol Biol. 183(4):591–610.
   PubMed Web of Science ®Google Scholar
• Ferrone FA, Hofrichter J, Eaton WA. 1985b. Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. J Mol Biol. 183(4):611–631.
   PubMed Web of Science ®Google Scholar
• Fields CR, Bengoa-Vergniory N, Wade-Martins R. 2019. Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front Mol Neurosci. 12:299.
   PubMed Web of Science ®Google Scholar
• Fink AL. 2006. The aggregation and fibrillation of α-synuclein. Acc Chem Res. 39(9):628–634.
   PubMed Web of Science ®Google Scholar
• Freyssin A, Page G, Fauconneau B, Rioux Bilan A. 2018. Natural polyphenols effects on protein aggregates in Alzheimer’s and Parkinson’s prion-like diseases. Neural Regen Res. 13(6):955–961.
   PubMed Web of Science ®Google Scholar
• Galamba N, Paiva A, Barreiros S, Simões P. 2019. Solubility of polar and nonpolar aromatic molecules in subcritical water: the role of the dielectric constant. J Chem Theory Comput. 15(11):6277–6293.
   PubMed Web of Science ®Google Scholar
• Galamba N, Pipolo S. 2018. On the binding free energy and molecular origin of sickle cell hemoglobin aggregation. J Phys Chem B. 122(30):7475–7483.
   PubMed Web of Science ®Google Scholar
• Galamba N. 2013. Water’s structure around hydrophobic solutes and the iceberg model. J Phys Chem B. 117(7):2153–2159.
   PubMed Web of Science ®Google Scholar
• Galamba N. 2014. Water tetrahedrons, hydrogen-bond dynamics, and the orientational mobility of water around hydrophobic solutes. J Phys Chem B. 118(15):4169–4176.
   PubMed Web of Science ®Google Scholar
• Galamba N. 2019. On the nonaggregation of normal adult hemoglobin and the aggregation of sickle cell hemoglobin. J Phys Chem B. 123(50):10735–10745.
   PubMed Web of Science ®Google Scholar
• Galamba N. 2021. Free energy convergence in short- and long-length hydrophobic hydration. J Mol Liq. 339:116699.
   Web of Science ®Google Scholar
• Galamba N. 2022. Aggregation of a Parkinson’s disease-related peptide: when does urea weaken hydrophobic interactions? ACS Chem Neurosci. 13(12):1769–1781.
   PubMed Web of Science ®Google Scholar
• Galkin O, Pan W, Filobelo L, Hirsch RE, Nagel RL, Vekilov PG. 2007. Two-step mechanism of homogeneous nucleation of sickle cell hemoglobin polymers. Biophys J. 93(3):902–913.
   PubMed Web of Science ®Google Scholar
• Galvagnion C, Brown JWP, Ouberai MM, Flagmeier P, Vendruscolo M, Buell AK, Sparr E, Dobson CM. 2016. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein. Proc Natl Acad Sci U S A. 113(26):7065–7070.
   PubMed Web of Science ®Google Scholar
• Galvagnion C, Buell AK, Meisl G, Michaels TCT, Vendruscolo M, Knowles TPJ, Dobson CM. 2015. Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol. 11(3):229–234.
   PubMed Web of Science ®Google Scholar
• Gao X, Carroni M, Nussbaum-Krammer C, Mogk A, Nillegoda NB, Szlachcic A, Guilbride DL, Saibil HR, Mayer MP, Bukau B. 2015. Human Hsp70 disaggregase reverses Parkinson’s-linked α-synuclein amyloid fibrils. Mol Cell. 59(5):781–793.
   PubMed Web of Science ®Google Scholar
• Garde S, Hummer G, García AE, Paulaitis ME, Pratt LR. 1996. Origin of entropy convergence in hydrophobic hydration and protein folding. Phys Rev Lett. 77(24):4966–4968.
   PubMed Web of Science ®Google Scholar
• Gautam S, Karmakar S, Batra R, Sharma P, Pradhan P, Singh J, Kundu B, Chowdhury PK. 2017. Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: a promising therapeutic alternative. Biochim Biophys Acta Proteins Proteom. 1865(5):589–603.
   PubMed Web of Science ®Google Scholar
• Gautam S, Karmakar S, Bose A, Chowdhury PK. 2014. β-Cyclodextrin and curcumin, a potent cocktail for disaggregating and/or inhibiting amyloids: a case study with α-synuclein. Biochemistry. 53(25):4081–4083.
   PubMed Web of Science ®Google Scholar
• Ghosh D, Mondal M, Mohite GM, Singh PK, Ranjan P, Anoop A, Ghosh S, Jha NN, Kumar A, Maji SK. 2013. The Parkinson’s disease-associated H50Q mutation accelerates α-synuclein aggregation in vitro. Biochemistry. 52(40):6925–6927.
   PubMed Web of Science ®Google Scholar
• Giasson BI, Murray IVJ, Trojanowski JQ, Lee VM-Y. 2001. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J Biol Chem. 276(4):2380–2386.
   PubMed Web of Science ®Google Scholar
• Giorgetti S, Greco C, Tortora P, Aprile F. 2018. Targeting amyloid aggregation: an overview of strategies and mechanisms. Int J Mol Sci. 19(9):2677.
   PubMed Web of Science ®Google Scholar
• Godawat R, Jamadagni SN, Garde S. 2009. Characterizing hydrophobicity of interfaces by using cavity formation, solute binding, and water correlations. Proc Natl Acad Sci U S A. 106(36):15119–15124.
   PubMed Web of Science ®Google Scholar
• Goedert M, Jakes R, Spillantini MG. 2017. The synucleinopathies: twenty years on. J Parkinsons Dis. 7(S1):S51–S69.
   PubMedGoogle Scholar
• Goldberg MS, Lansbury PTJr. 2000. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? Nat Cell Biol. 2(7):E115–E119.
   PubMed Web of Science ®Google Scholar
• Gopalsamy A, Aulabaugh AE, Barakat A, Beaumont KC, Cabral S, Canterbury DP, Casimiro-Garcia A, Chang JS, Chen MZ, Choi C, et al. 2021. PF-07059013: a noncovalent modulator of hemoglobin for treatment of sickle cell disease. J Med Chem. 64(1):326–342.
   PubMed Web of Science ®Google Scholar
• Gorecki M, Votano JR, Rich A. 1980. Peptide inhibitors of sickle hemoglobin aggregation: effect of hydrophobicity. Biochemistry. 19(8):1564–1568.
   PubMed Web of Science ®Google Scholar
• Granick S, Bae SC. 2008. A curious antipathy for water. Science. 322(5907):1477–1478.
   PubMed Web of Science ®Google Scholar
• Graziano G. 2005. Entropy convergence in the hydration thermodynamics of n-alcohols. J Phys Chem B. 109(24):12160–12166.
   PubMed Web of Science ®Google Scholar
• Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI. 2005. The E46K mutation in α-synuclein increases amyloid fibril formation. J Biol Chem. 280(9):7800–7807.
   PubMed Web of Science ®Google Scholar
• Grunwald E, Steel C. 1995. Solvent reorganization and thermodynamic enthalpy–entropy compensation. J Am Chem Soc. 117(21):5687–5692.
   Web of Science ®Google Scholar
• Guzzo A, Delarue P, Rojas A, Nicolaï A, Maisuradze GG, Senet P. 2022. Wild-type α-synuclein and variants occur in different disordered dimers and pre-fibrillar conformations in early stage of aggregation. Front Mol Biosci. 9:910104.
   PubMed Web of Science ®Google Scholar
• Harrington DJ, Adachi K, Royer WE. 1997. The high resolution crystal structure of deoxyhemoglobin S. J Mol Biol. 272(3):398–407.
   PubMed Web of Science ®Google Scholar
• Harrington JP, Elbaum D, Bookchin RM, Wittenberg JB, Nagel RL. 1977. Ligand kinetics of hemoglobin S containing erythrocytes. Proc Natl Acad Sci U S A. 74(1):203–206.
   PubMed Web of Science ®Google Scholar
• Henríquez G, Gomez A, Guerrero E, Narayan M. 2020. Potential role of natural polyphenols against protein aggregation toxicity: in vitro, in vivo, and clinical studies. ACS Chem Neurosci. 11(19):2915–2934.
   PubMed Web of Science ®Google Scholar
• Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, Cellmer T, Dunkelberger EB, Conrey A, Thein SL, et al. 2021. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood. 138(13):1172–1181.
   PubMed Web of Science ®Google Scholar
• Herrera FE, Chesi A, Paleologou KE, Schmid A, Munoz A, Vendruscolo M, Gustincich S, Lashuel HA, Carloni P. 2008. Inhibition of α-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLOS One. 3(10):e3394.
   PubMed Web of Science ®Google Scholar
• Hofrichter J, Ross PD, Eaton WA. 1974. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci U S A. 71(12):4864–4868.
   PubMed Web of Science ®Google Scholar
• Hong D-P, Fink AL, Uversky VN. 2008. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J Mol Biol. 383(1):214–223.
   PubMed Web of Science ®Google Scholar
• Horn HW, Swope WC, Pitera JW, Madura JD, Dick TJ, Hura GL, Head-Gordon T. 2004. Development of an improved four-site water model for biomolecular simulations: TIP4P-Ew. J Chem Phys. 120(20):9665–9678.
   PubMed Web of Science ®Google Scholar
• Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. 2006. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins. 65(3):712–725.
   PubMed Web of Science ®Google Scholar
• Horsley JR, Jovcevski B, Pukala TL, Abell AD. 2022. Designer D-peptides targeting the N-terminal region of α-synuclein to prevent Parkinsonian-associated fibrilization and cytotoxicity. Biochim Biophys Acta Proteins Proteom. 1870(10):140826.
   PubMed Web of Science ®Google Scholar
• Huang DM, Chandler D. 2000. Temperature and length scale dependence of hydrophobic effects and their possible implications for protein folding. Proc Natl Acad Sci U S A. 97(15):8324–8327.
   PubMed Web of Science ®Google Scholar
• Hummer G, Garde S, Garcia AE, Pohorille A, Pratt LR. 1996. An information theory model of hydrophobic interactions. Proc Natl Acad Sci U S A. 93(17):8951–8955.
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. 2013. The pharmacology of l-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev. 65(1):171–222.
   PubMed Web of Science ®Google Scholar
• Imaga NA. 2013. Phytomedicines and nutraceuticals: alternative therapeutics for sickle cell anemia. ScientificWorldJournal. 2013:269659.
   PubMedGoogle Scholar
• Ingram VM. 1956. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 178(4537):792–794.
   PubMed Web of Science ®Google Scholar
• Ingram VM. 1957. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 180(4581):326–328.
   PubMed Web of Science ®Google Scholar
• Itano HA. 1953. Solubilities of naturally occurring mixtures of human hemoglobin. Arch Biochem Biophys. 47(1):148–159.
   PubMed Web of Science ®Google Scholar
• Ivanova M, Jasuja R, Krasnosselskaia L, Josephs R, Wang Z, Ding M, Horiuchi K, Adachi K, Ferrone FA. 2001. Flexibility and nucleation in sickle hemoglobin. J Mol Biol. 314(4):851–861.
   PubMed Web of Science ®Google Scholar
• Iyamu EW, Turner EA, Asakura T. 2002. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent: antisickling effects of Nix-0699. Br J Haematol. 118(1):337–343.
   PubMed Web of Science ®Google Scholar
• Jamadagni SN, Godawat R, Garde S. 2011. Hydrophobicity of proteins and interfaces: insights from density fluctuations. Annu Rev Chem Biomol Eng. 2(1):147–171.
   PubMedGoogle Scholar
• Javed H, Nagoor Meeran MF, Azimullah S, Adem A, Sadek B, Ojha SK. 2018. Plant extracts and phytochemicals targeting α-synuclein aggregation in Parkinson’s disease models. Front Pharmacol. 9:1555.
   PubMed Web of Science ®Google Scholar
• Jenner P. 2003. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinsonʼs disease. Curr Opin Neurol. 16:S3–S7.
   PubMed Web of Science ®Google Scholar
• Jia L, Wang Y, Sang J, Cui W, Zhao W, Wei W, Chen B, Lu F, Liu F. 2019. Dihydromyricetin inhibits α-synuclein aggregation, disrupts preformed fibrils, and protects neuronal cells in culture against amyloid-induced cytotoxicity. J Agric Food Chem. 67(14):3946–3955.
   PubMed Web of Science ®Google Scholar
• Kapoor S, Little JA, Pecker LH. 2018. Advances in the treatment of sickle cell disease. Mayo Clin Proc. 93(12):1810–1824.
   PubMed Web of Science ®Google Scholar
• Karpinar DP, Balija MBG, Kügler S, Opazo F, Rezaei-Ghaleh N, Wender N, Kim H-Y, Taschenberger G, Falkenburger BH, Heise H, et al. 2009. Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson’s disease models. EMBO J. 28(20):3256–3268.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, et al. 2018. Sickle cell disease. Nat Rev Dis Primers. 4(1):18010.
   PubMedGoogle Scholar
• Kato GJ, Steinberg MH, Gladwin MT. 2017. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 127(3):750–760.
   PubMed Web of Science ®Google Scholar
• Kauzmann W. 1959. Some factors in the interpretation of protein denaturation. Adv Protein Chem. 14:1–63.
   PubMedGoogle Scholar
• Khatoon SS, Rehman M, Rahman A. 2018. The role of natural products in Alzheimer’s and Parkinson’s disease. Stud Nat Prod Chem. 56:69–127.
   Google Scholar
• Kim YS, Lim D, Kim JY, Kang SJ, Kim Y-H, Im H. 2009. β-Sheet-breaking peptides inhibit the fibrillation of human α-synuclein. Biochem Biophys Res Commun. 387(4):682–687.
   PubMed Web of Science ®Google Scholar
• Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat Genet. 18(2):106–108.
   PubMed Web of Science ®Google Scholar
• Kubota S, Chang CT, Samejima T, Yang JT. 1976. Oligopeptides as potential antiaggregation agent for proteins: hemoglobin S gel and insulin dimer. J Am Chem Soc. 98(9):2677–2678.
   PubMed Web of Science ®Google Scholar
• Kuczera K, Gao J, Tidor B, Karplus M. 1990. Free energy of sickling: a simulation analysis. Proc Natl Acad Sci U S A. 87(21):8481–8485.
   PubMed Web of Science ®Google Scholar
• Lamberto GR, Binolfi A, Orcellet ML, Bertoncini CW, Zweckstetter M, Griesinger C, Fernández CO. 2009. Structural and mechanistic basis behind the inhibitory interaction of PcTS on α-synuclein amyloid fibril formation. Proc Natl Acad Sci U S A. 106(50):21057–21062.
   PubMed Web of Science ®Google Scholar
• Lamberto GR, Torres-Monserrat V, Bertoncini CW, Salvatella X, Zweckstetter M, Griesinger C, Fernández CO. 2011. Toward the discovery of effective polycyclic inhibitors of α-synuclein amyloid assembly. J Biol Chem. 286(37):32036–32044.
   PubMed Web of Science ®Google Scholar
• Landeck N, Strathearn KE, Ysselstein D, Buck K, Dutta S, Banerjee S, Lv Z, Hulleman JD, Hindupur J, Lin L-K, et al. 2020. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein. Mol Neurodegener. 15(1):49.
   PubMed Web of Science ®Google Scholar
• Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT. 2002. Amyloid pores from pathogenic mutations. Nature. 418(6895):291.
   PubMed Web of Science ®Google Scholar
• Lashuel HA, Overk CR, Oueslati A, Masliah E. 2013. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 14(1):38–48.
   PubMed Web of Science ®Google Scholar
• Latawiec D, Herrera F, Bek A, Losasso V, Candotti M, Benetti F, Carlino E, Kranjc A, Lazzarino M, Gustincich S, et al. 2010. Modulation of alpha-synuclein aggregation by dopamine analogs. PLOS One. 5(2):e9234.
   PubMed Web of Science ®Google Scholar
• Lee B. 1991. Solvent reorganization contribution to the transfer thermodynamics of small nonpolar molecules. Biopolymers. 31(8):993–1008.
   PubMed Web of Science ®Google Scholar
• Lee E-N, Cho H-J, Lee C-H, Lee D, Chung KC, Paik SR. 2004. Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of α-synuclein. Biochemistry. 43(12):3704–3715.
   PubMed Web of Science ®Google Scholar
• Lee S-J, Jeon H, Kandror KV. 2008. Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles. Acta Neurobiol Exp. 68(4):509–515.
   PubMed Web of Science ®Google Scholar
• Li B, Ge P, Murray KA, Sheth P, Zhang M, Nair G, Sawaya MR, Shin WS, Boyer DR, Ye S, et al. 2018. Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel. Nat Commun. 9(1):3609.
   PubMed Web of Science ®Google Scholar
• Li H-T, Lin D-H, Luo X-Y, Zhang F, Ji L-N, Du H-N, Song G-Q, Hu J, Zhou J-W, Hu H-Y. 2005. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 272(14):3661–3672.
   PubMedGoogle Scholar
• Li J, Uversky VN, Fink AL. 2001. Effect of familial Parkinson’s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry. 40(38):11604–11613.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao C, Luo F, Liu Z, Gui X, Luo Z, Zhang X, Li D, Liu C, Li X. 2018. Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy. Cell Res. 28(9):897–903.
   PubMed Web of Science ®Google Scholar
• Liang Z, Chan HYE, Lee MM, Chan MK. 2021. A SUMO1-derived peptide targeting SUMO-interacting motif inhibits α-synuclein aggregation. Cell Chem Biol. 28(2):180–190.e6.
   PubMed Web of Science ®Google Scholar
• Lorenzen N, Nielsen SB, Yoshimura Y, Vad BS, Andersen CB, Betzer C, Kaspersen JD, Christiansen G, Pedersen JS, Jensen PH, et al. 2014. How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro. J Biol Chem. 289(31):21299–21310.
   PubMed Web of Science ®Google Scholar
• Lu L, Li X, Vekilov PG, Karniadakis GE. 2016. Probing the twisted structure of sickle hemoglobin fibers via particle simulations. Biophys J. 110(9):2085–2093.
   PubMed Web of Science ®Google Scholar
• Lu L, Li Z, Li H, Li X, Vekilov PG, Karniadakis GE. 2019. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies. Sci Adv. 5(8):eaax3905.
   PubMed Web of Science ®Google Scholar
• Luk KC, Mills IP, Trojanowski JQ, Lee VM-Y. 2008. Interactions between Hsp70 and the hydrophobic core of α-synuclein inhibit fibril assembly. Biochemistry. 47(47):12614–12625.
   PubMed Web of Science ®Google Scholar
• Lum K, Chandler D, Weeks JD. 1999. Hydrophobicity at small and large length scales. J Phys Chem B. 103(22):4570–4577.
   Web of Science ®Google Scholar
• Ma J, Gao J, Wang J, Xie A. 2019. Prion-like mechanisms in Parkinson’s disease. Front Neurosci. 13:552.
   PubMedGoogle Scholar
• Madine J, Doig AJ, Middleton DA. 2008. Design of an N-methylated peptide inhibitor of α-synuclein aggregation guided by solid-state NMR. J Am Chem Soc. 130(25):7873–7881.
   PubMed Web of Science ®Google Scholar
• Maity D, Pal D. 2021. Molecular dynamics of hemoglobin reveals structural alterations and explains the interactions driving sickle cell fibrillation. J Phys Chem B. 125(35):9921–9933.
   PubMed Web of Science ®Google Scholar
• Makin S. 2018. The amyloid hypothesis on trial. Nature. 559(7715):S4–S7.
   PubMed Web of Science ®Google Scholar
• Maroteaux L, Campanelli J, Scheller R. 1988. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 8(8):2804–2815.
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. 2000. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science. 287(5456):1265–1269.
   PubMed Web of Science ®Google Scholar
• Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M. 2006. Small molecule inhibitors of α-synuclein filament assembly. Biochemistry. 45(19):6085–6094.
   PubMed Web of Science ®Google Scholar
• Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DMA, Hasegawa M. 2013. Prion-like spreading of pathological α-synuclein in brain. Brain. 136(Pt 4):1128–1138.
   PubMed Web of Science ®Google Scholar
• Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ischiropoulos H. 2007. Cellular oligomerization of α-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J Biol Chem. 282(43):31621–31630.
   PubMed Web of Science ®Google Scholar
• Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H. 2006. Cytosolic catechols inhibit -synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci. 26(39):10068–10078.
   PubMed Web of Science ®Google Scholar
• Meade RM, Watt KJC, Williams RJ, Mason JM. 2021. A downsized and optimised intracellular library-derived peptide prevents alpha-synuclein primary nucleation and toxicity without impacting upon lipid binding. J Mol Biol. 433(24):167323.
   PubMed Web of Science ®Google Scholar
• Mehanna A. 2001. Sickle cell anemia and antisickling agents then and now. Curr Med Chem. 8(2):79–88.
   PubMed Web of Science ®Google Scholar
• Meng X, Munishkina LA, Fink AL, Uversky VN. 2009. Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation. Biochemistry. 48(34):8206–8224.
   PubMed Web of Science ®Google Scholar
• Meng X, Munishkina LA, Fink AL, Uversky VN. 2010. Effects of various flavonoids on the α-synuclein fibrillation process. Parkinsons Dis. 2010:1–16.
   Web of Science ®Google Scholar
• Metaferia B, Cellmer T, Dunkelberger EB, Li Q, Henry ER, Hofrichter J, Staton D, Hsieh MM, Conrey AK, Tisdale JF, et al. 2022. Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease. Proc Natl Acad Sci U S A. 119(40):e2210779119.
   PubMed Web of Science ®Google Scholar
• Mohammad-Beigi H, Aliakbari F, Sahin C, Lomax C, Tawfike A, Schafer NP, Amiri-Nowdijeh A, Eskandari H, Møller IM, Hosseini-Mazinani M, et al. 2019. Oleuropein derivatives from olive fruit extracts reduce α-synuclein fibrillation and oligomer toxicity. J Biol Chem. 294(11):4215–4232.
   PubMed Web of Science ®Google Scholar
• Mohankumar T, Chandramohan V, Lalithamba HS, Jayaraj RL, Kumaradhas P, Sivanandam M, Hunday G, Vijayakumar R, Balakrishnan R, Manimaran D, et al. 2020. Design and molecular dynamic investigations of 7,8-dihydroxyflavone derivatives as potential neuroprotective agents against alpha-synuclein. Sci Rep. 10(1):599.
   PubMed Web of Science ®Google Scholar
• Moody JO, Ojo OO, Omotade OO, Adeyemo AA, Olumese PE, Ogundipe OO. 2003. Anti-sickling potential of a Nigerian herbal formula (Ajawaron HF) and the major plant component (Cissus populnea L. CPK). Phytother Res. 17(10):1173–1176.
   PubMed Web of Science ®Google Scholar
• Moon HE, Paek SH. 2015. Mitochondrial dysfunction in Parkinson’s disease. Exp Neurobiol. 24(2):103–116.
   PubMed Web of Science ®Google Scholar
• Mpiana PT, Tshibangu DST, Shetonde OM, Ngbolua KN. 2007. In vitro antidrepanocytary activity (anti-sickle cell anemia) of some Congolese plants. Phytomedicine. 14(2–3):192–195.
   PubMed Web of Science ®Google Scholar
• Nagel RL, Johnson J, Bookchin RM, Garel MC, Rosa J, Schiliro G, Wajcman H, Labie D, Moo-Penn W, Castro O. 1980. β-Chain contact sites in the haemoglobin S polymer. Nature. 283(5750):832–834.
   PubMed Web of Science ®Google Scholar
• Nakagawa A, Lui FE, Wassaf D, Yefidoff-Freedman R, Casalena D, Palmer MA, Meadows J, Mozzarelli A, Ronda L, Abdulmalik O, et al. 2014. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem Biol. 9(10):2318–2325.
   PubMed Web of Science ®Google Scholar
• Neddenriep B, Calciano A, Conti D, Sauve E, Paterson M, Bruno EA, Moffet D. 2011. Short peptides as inhibitors of amyloid aggregation. Open Biotechnol J. 5(1):39–46.
   PubMedGoogle Scholar
• Ni X, McGlinchey RP, Jiang J, Lee JC. 2019. Structural insights into α-synuclein fibril polymorphism: effects of Parkinson’s disease-related C-terminal truncations. J Mol Biol. 431(19):3913–3919.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Zerez CR, Akiyama DS, Tanaka KR. 1998. Oral l-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol. 58(2):117–121.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Zerez CR, Akiyama DS, Tanaka KR. 1997. Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells. J Lab Clin Med. 130(1):83–90.
   PubMed Web of Science ®Google Scholar
• Noguchi CT, Schechter AN. 1977. Effects of amino acids on gelation kinetics and solubility of sickle hemoglobin. Biochem Biophys Res Commun. 74(2):637–642.
   PubMed Web of Science ®Google Scholar
• Noguchi CT, Schechter AN. 1978. Inhibition of sickle hemoglobin gelation by amino acids and related compounds. Biochemistry. 17(25):5455–5459.
   PubMed Web of Science ®Google Scholar
• Noguchi CT, Schechter AN. 1985. Sickle hemoglobin polymerization in solution and in cells. Annu Rev Biophys Biophys Chem. 14(1):239–263.
   PubMedGoogle Scholar
• Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM-Y. 2005. Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem. 280(22):21212–21219.
   PubMed Web of Science ®Google Scholar
• Norris EH, Giasson BI, Lee VM-Y. 2004. α-Synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol. 60:17–54.
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Tanford C. 1971. The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. J Biol Chem. 246(7):2211–2217.
   PubMed Web of Science ®Google Scholar
• Oder E, Safo MK, Abdulmalik O, Kato GJ. 2016. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Br J Haematol. 175(1):24–30.
   PubMed Web of Science ®Google Scholar
• Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, et al. 2016. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 175(1):141–153.
   PubMed Web of Science ®Google Scholar
• Olagunju MO, Loschwitz J, Olubiyi OO, Strodel B. 2022. Multiscale MD simulations of wild-type and sickle hemoglobin aggregation. Proteins. 90(11):1811–1824.
   PubMed Web of Science ®Google Scholar
• Olubiyi OO, Olagunju MO, Oni JO, Olubiyi AO. 2018. Structural basis of antisickling effects of selected FDA approved drugs: a drug repurposing study. Curr Comput Aided Drug Des. 14(2):106–116.
   PubMed Web of Science ®Google Scholar
• Olubiyi OO, Olagunju MO, Strodel B. 2019. Rational drug design of peptide-based therapies for sickle cell disease. Molecules. 24(24):4551.
   PubMed Web of Science ®Google Scholar
• Ono K, Yamada M. 2006. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem. 97(1):105–115.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR. 2018. A new step in the treatment of sickle cell disease: published as part of the Biochemistry series “Biochemistry to Bedside”. Biochemistry. 57(5):470–471.
   PubMedGoogle Scholar
• Padlan EA, Love WA. 1985a. Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal. J Biol Chem. 260(14):8280–8291.
   PubMed Web of Science ®Google Scholar
• Padlan EA, Love WE. 1985b. Refined crystal structure of deoxyhemoglobin S. I. Restrained least-squares refinement at 3.0-8 resolution. J Biol Chem. 260(14):8272–8279.
   PubMed Web of Science ®Google Scholar
• Pagare PP, Rastegar A, Abdulmalik O, Omar AM, Zhang Y, Fleischman A, Safo MK. 2022. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. Expert Opin Ther Pat. 32(2):115–130.
   PubMed Web of Science ®Google Scholar
• Palazzi L, Bruzzone E, Bisello G, Leri M, Stefani M, Bucciantini M, Polverino de Laureto P. 2018. Oleuropein aglycone stabilizes the monomeric α-synuclein and favours the growth of non-toxic aggregates. Sci Rep. 8(1):8337.
   PubMedGoogle Scholar
• Park S-Y, Yokoyama T, Shibayama N, Shiro Y, Tame JRH. 2006. 1.25 Å resolution crystal structures of human haemoglobin in the oxy, deoxy and carbonmonoxy forms. J Mol Biol. 360(3):690–701.
   PubMed Web of Science ®Google Scholar
• Pauling LL, Itano HA, Singer SJ, Wells IC. 1949. Sickle cell anemia, a molecular disease. Science. 110(2865):543–548.
   PubMed Web of Science ®Google Scholar
• Perni M, Flagmeier P, Limbocker R, Cascella R, Aprile FA, Galvagnion C, Heller GT, Meisl G, Chen SW, Kumita JR, et al. 2018. Multistep inhibition of α-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine. ACS Chem Biol. 13(8):2308–2319.
   PubMed Web of Science ®Google Scholar
• Perni M, Galvagnion C, Maltsev A, Meisl G, Müller MBD, Challa PK, Kirkegaard JB, Flagmeier P, Cohen SIA, Cascella R, et al. 2017. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci U S A. 114(6):E1009–E1017.
   PubMed Web of Science ®Google Scholar
• Perutz MF, Liquori AM, Eirich F. 1951. X-ray and solubility studies of the haemoglobin of sickle-cell anaemia patients. Nature. 167(4258):929–931.
   PubMed Web of Science ®Google Scholar
• Perutz MF, Rossmann MG, Cullis AF, Muirhead H, Will G, North ACT. 1960. Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-Å. Resolution, obtained by X-ray analysis. Nature. 185(4711):416–422.
   PubMed Web of Science ®Google Scholar
• Perutz MF. 1970. Stereochemistry of cooperative effects in haemoglobin: haem–haem interaction and the problem of allostery. Nature. 228(5273):726–739.
   PubMed Web of Science ®Google Scholar
• Piel FB, Steinberg MH, Rees DC. 2017. Sickle cell disease. N Engl J Med. 376(16):1561–1573.
   PubMed Web of Science ®Google Scholar
• Poillon W, Kim B. 1990. 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood. 76(5):1028–1036.
   PubMed Web of Science ®Google Scholar
• Poillon WN, Bertles JF. 1979. Deoxygenated sickle hemoglobin. Effects of lyotropic salts on its solubility. J Biol Chem. 254(9):3462–3467.
   PubMed Web of Science ®Google Scholar
• Poillon WN, Kim BC, Labotka RJ, Hicks CU, Kark JA. 1995. Antisickling effects of 2,3-diphosphoglycerate depletion. Blood. 85(11):3289–3296.
   PubMed Web of Science ®Google Scholar
• Poillon WN, Kim BC, Welty EV, Walder JA. 1986. The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S. Arch Biochem Biophys. 249(2):301–305.
   PubMed Web of Science ®Google Scholar
• Poillon WN. 1982. Noncovalent inhibitors of sickle hemoglobin gelation: effects of aryl-substituted alanines. Biochemistry. 21(6):1400–1406.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. 1997. Mutation in the -synuclein gene identified in families with Parkinson’s disease. Science. 276(5321):2045–2047.
   PubMed Web of Science ®Google Scholar
• Popova B, Wang D, Rajavel A, Dhamotharan K, Lázaro DF, Gerke J, Uhrig JF, Hoppert M, Outeiro TF, Braus GH. 2021. Identification of two novel peptides that inhibit α-synuclein toxicity and aggregation. Front Mol Neurosci. 14:659926.
   PubMed Web of Science ®Google Scholar
• Pratt LR, Chandler D. 1977. Theory of the hydrophobic effect. J Chem Phys. 67(8):3683–3704.
   Web of Science ®Google Scholar
• Pujols J, Peña-Díaz S, Lázaro DF, Peccati F, Pinheiro F, González D, Carija A, Navarro S, Conde-Giménez M, García J, et al. 2018. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc Natl Acad Sci U S A. 115(41):10481–10486.
   PubMed Web of Science ®Google Scholar
• Quezado ZMN, Kamimura S, Smith M, Wang X, Heaven MR, Jana S, Vogel S, Zerfas P, Combs CA, Almeida LEF, et al. 2022. Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model. Blood Cells Mol Dis. 95:102660.
   PubMed Web of Science ®Google Scholar
• Rao JN, Dua V, Ulmer TS. 2008. Characterization of α-synuclein interactions with selected aggregation-inhibiting small molecules. Biochemistry. 47(16):4651–4656.
   PubMed Web of Science ®Google Scholar
• Rao JN, Jao CC, Hegde BG, Langen R, Ulmer TS. 2010. A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins. J Am Chem Soc. 132(25):8657–8668.
   PubMed Web of Science ®Google Scholar
• Rezaeian N, Shirvanizadeh N, Mohammadi S, Nikkhah M, Arab SS. 2017. The inhibitory effects of biomimetically designed peptides on α-synuclein aggregation. Arch Biochem Biophys. 634:96–106.
   PubMed Web of Science ®Google Scholar
• Ribeil J-A, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W, et al. 2017. Gene therapy in a patient with sickle cell disease. N Engl J Med. 376(9):848–855.
   PubMed Web of Science ®Google Scholar
• Robertson AD, Murphy KP. 1997. Protein structure and the energetics of protein stability. Chem Rev. 97(5):1251–1268.
   PubMed Web of Science ®Google Scholar
• Rochet J-C, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT. 2004. Interactions among α-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson’s disease. J Mol Neurosci. 23(1–2):23–34.
   PubMed Web of Science ®Google Scholar
• Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, et al. 2015. Structure of the toxic core of α-synuclein from invisible crystals. Nature. 525(7570):486–490.
   PubMed Web of Science ®Google Scholar
• Rolan P, Parker J, Gray S, Weatherley B, Ingram J, Leavens W, Wootton R, Posner J. 1993. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects. Br J Clin Pharmacol. 35(4):419–425.
   PubMed Web of Science ®Google Scholar
• Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A. 1999. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle: NTN and GDNF protect nigrostriatal DA neurons. Eur J Neurosci. 11(5):1554–1566.
   PubMed Web of Science ®Google Scholar
• Ross PD, Hofrichter J, Eaton WA. 1977. Thermodynamics of gelation of sickle cell deoxyhemoglobin. J Mol Biol. 115(2):111–134.
   PubMed Web of Science ®Google Scholar
• Ross PD, Subramanian S. 1977. Inhibition of sickle cell hemoglobin gelation by some aromatic compounds. Biochem Biophys Res Commun. 77(4):1217–1223.
   PubMed Web of Science ®Google Scholar
• Ruggeri FS, Longo G, Faggiano S, Lipiec E, Pastore A, Dietler G. 2015. Infrared nanospectroscopy characterization of oligomeric and fibrillar aggregates during amyloid formation. Nat Commun. 6(1):7831.
   PubMedGoogle Scholar
• Rumen N. 1975. Inhibition of sickling in erythrocytes by amino acids. Blood. 45(1):45–48.
   PubMed Web of Science ®Google Scholar
• Russu IM, Lin AKLC, Yang CP, Ho C. 1986. Molecular basis for the antisickling activity of aromatic amino acids and related compounds: a proton nuclear magnetic resonance investigation. Biochemistry. 25(4):808–815.
   PubMed Web of Science ®Google Scholar
• Saffari B, Amininasab M. 2021. Crocin inhibits the fibrillation of human α-synuclein and disassembles mature fibrils: experimental findings and mechanistic insights from molecular dynamics simulation. ACS Chem Neurosci. 12(21):4037–4057.
   PubMed Web of Science ®Google Scholar
• Salinas Cisneros G, Thein SL. 2020. Recent advances in the treatment of sickle cell disease. Front Physiol. 11:435.
   PubMed Web of Science ®Google Scholar
• Samuel RE, Salmon ED, Briehl RW. 1990. Nucleation and growth of fibres and gel formation in sickle cell haemoglobin. Nature. 345(6278):833–835.
   PubMed Web of Science ®Google Scholar
• Santos J, Gracia P, Navarro S, Peña-Díaz S, Pujols J, Cremades N, Pallarès I, Ventura S. 2021. α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity. Nat Commun. 12(1):3752.
   PubMed Web of Science ®Google Scholar
• Schechter AN, Noguchi CT, Schwartz WA. 1978. Amino acids and peptides as inhibitors of sickle hemoglobin gelation. In: Winslow Caughey, editor. Biochemical and clinical aspects of hemoglobin abnormalities. New York: Elsevier; p. 129–141.
   Google Scholar
• Schechter AN. 1980. Stereospecific inhibitors of the gelation of sickle hemoglobin. Hemoglobin. 4(3–4):335–345.
   PubMed Web of Science ®Google Scholar
• Sciarretta KL, Gordon DJ, Meredith SC. 2006. Peptide-based inhibitors of amyloid assembly. In: Indu Kheterpal and Ronald Wetzel, editors. Methods in enzymology. Vol. 413. Amsterdam: Elsevier; p. 273–312.
   Google Scholar
• Sedlmeier F, Horinek D, Netz RR. 2011. Entropy and enthalpy convergence of hydrophobic solvation beyond the hard-sphere limit. J Chem Phys. 134(5):055105.
   PubMed Web of Science ®Google Scholar
• Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. 2000. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A. 97(9):4897–4902.
   PubMed Web of Science ®Google Scholar
• Singh H, Sharma S. 2022. Hydration of linear alkanes is governed by the small length-scale hydrophobic effect. J Chem Theory Comput. 18(6):3805–3813.
   PubMed Web of Science ®Google Scholar
• Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK. 2013. Curcumin modulates α-synuclein aggregation and toxicity. ACS Chem Neurosci. 4(3):393–407.
   PubMed Web of Science ®Google Scholar
• Soto C. 2003. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 4(1):49–60.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. 1998. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett. 251(3):205–208.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 95(11):6469–6473.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. 1997. α-Synuclein in Lewy bodies. Nature. 388(6645):839–840.
   PubMed Web of Science ®Google Scholar
• Stefani M, Rigacci S. 2013. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Sci. 14(6):12411–12457.
   PubMed Web of Science ®Google Scholar
• Stephens AD, Zacharopoulou M, Moons R, Fusco G, Seetaloo N, Chiki A, Woodhams PJ, Mela I, Lashuel HA, Phillips JJ, et al. 2020. Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity. Nat Commun. 11(1):2820.
   PubMed Web of Science ®Google Scholar
• Stillinger FH. 1973. Structure in aqueous solutions of nonpolar solutes from the standpoint of scaled-particle theory. J Solution Chem. 2(2–3):141–158.
   Web of Science ®Google Scholar
• Stoker TB, Barker RA. 2020. Recent developments in the treatment of Parkinson’s disease. F1000Res. 9:862.
   Google Scholar
• Strader MB, Liang H, Meng F, Harper J, Ostrowski DA, Henry ER, Shet AS, Eaton WA, Thein SL, Alayash AI. 2019. Interactions of an anti-sickling drug with hemoglobin in red blood cells from a patient with sickle cell anemia. Bioconjug Chem. 30(3):568–571.
   PubMed Web of Science ®Google Scholar
• Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, McCampbell A, Leblanc G, Venkateswaran A, Nurmi A, et al. 2017. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 6(1):6.
   PubMed Web of Science ®Google Scholar
• Swift R, Abdulmalik O, Chen Q, Asakura T, Gustafson K, Simon JE, Zaman V, Quiusky KA, Hassell KL, Shapira I, et al. 2016. SCD-101: a new anti-sickling drug reduces pain and fatigue and improves red blood cell shape in peripheral blood of patients with sickle cell disease. Blood. 128(22):121.
   Web of Science ®Google Scholar
• Syed MM, Doshi PJ, Kulkarni MV, Dhavale DD, Kadam NS, Kate SL, Doshi JB, Sharma N, Uppuladinne M, Sonavane U, et al. 2019. Alizarin interaction with sickle hemoglobin: elucidation of their anti-sickling properties by multi-spectroscopic and molecular modeling techniques. J Biomol Struct Dyn. 37(17):4614–4631.
   PubMed Web of Science ®Google Scholar
• Tamoliunas K, Galamba N. 2020. Protein denaturation, zero entropy temperature, and the structure of water around hydrophobic and amphiphilic solutes. J Phys Chem B. 124(48):10994–11006.
   PubMed Web of Science ®Google Scholar
• Tanford C. 1980. The hydrophobic effect: formation of micelles and biological membranes. 2nd ed. New York: Wiley.
   Google Scholar
• Tatenhorst L, Eckermann K, Dambeck V, Fonseca-Ornelas L, Walle H, Lopes da Fonseca T, Koch JC, Becker S, Tönges L, Bähr M, et al. 2016. Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease. Acta Neuropathol Commun. 4(1):39.
   PubMedGoogle Scholar
• Telen MJ, Malik P, Vercellotti GM. 2019. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov. 18(2):139–158.
   PubMed Web of Science ®Google Scholar
• Tinku, Paithankar H, Rane AR, Hosur RV, Choudhary S. 2021. Mechanistic insights into chalcone butein-induced inhibition of α-synuclein fibrillation: biophysical and in silico studies. J Mol Liq. 334:116105.
   Web of Science ®Google Scholar
• Tisdale JF, Thein SL, Eaton WA. 2020. Treating sickle cell anemia. Science. 367(6483):1198–1199.
   PubMed Web of Science ®Google Scholar
• Torpey JH, Meade RM, Mistry R, Mason JM, Madine J. 2020. Insights into peptide inhibition of alpha-synuclein aggregation. Front Neurosci. 14:561462.
   PubMed Web of Science ®Google Scholar
• Tóth G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet J-C, Galvagnion C, Skibinski G, et al. 2014. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson’s disease. PLOS One. 9(2):e87133.
   PubMed Web of Science ®Google Scholar
• Tripathi T. 2020. A Master Regulator of α-synuclein aggregation. ACS Chem Neurosci. 11(10):1376–1378.
   PubMed Web of Science ®Google Scholar
• Trojanowski JQ, Lee VM-Y. 2003. Parkinson’s disease and related α-synucleinopathies are brain amyloidoses. Ann N Y Acad Sci. 991(1):107–110.
   PubMedGoogle Scholar
• Tu P, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VM-Y. 1998. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol. 44(3):415–422.
   PubMed Web of Science ®Google Scholar
• Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, Kloepper KD, Courtney J, Kim M, Barclay JK, Kendall AM, et al. 2016. Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat Struct Mol Biol. 23(5):409–415.
   PubMed Web of Science ®Google Scholar
• Uéda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. 1993. Molecular cloning of CDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 90(23):11282–11286.
   PubMed Web of Science ®Google Scholar
• Ulamec SM, Maya-Martinez R, Byrd EJ, Dewison KM, Xu Y, Willis LF, Sobott F, Heath GR, van Oosten Hawle P, Buchman VL, et al. 2022. Single residue modulators of amyloid formation in the N-terminal P1-region of α-synuclein. Nat Commun. 13(1):4986.
   PubMed Web of Science ®Google Scholar
• Ulmer TS, Bax A, Cole NB, Nussbaum RL. 2005. Structure and dynamics of micelle-bound human α-synuclein. J Biol Chem. 280(10):9595–9603.
   PubMed Web of Science ®Google Scholar
• Uversky V, Eliezer D. 2009. Biophysics of Parkinsons disease: structure and aggregation of α-synuclein. Curr Protein Pept Sci. 10(5):483–499.
   PubMed Web of Science ®Google Scholar
• Uversky VN, Li J, Fink AL. 2001. Evidence for a partially folded intermediate in α-synuclein fibril formation. J Biol Chem. 276(14):10737–10744.
   PubMed Web of Science ®Google Scholar
• Uversky VN. 2007. Neuropathology, biochemistry, and biophysics of α-synuclein aggregation. J Neurochem. 103:17–37.
   PubMed Web of Science ®Google Scholar
• Valiente-Gabioud AA, Miotto MC, Chesta ME, Lombardo V, Binolfi A, Fernández CO. 2016. Phthalocyanines as molecular scaffolds to block disease-associated protein aggregation. Acc Chem Res. 49(5):801–808.
   PubMed Web of Science ®Google Scholar
• Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, et al. 2019. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 18(6):463–477.
   PubMed Web of Science ®Google Scholar
• van Dijk MJ, Rab MAE, van Oirschot BA, Bos J, Derichs C, Rijneveld AW, Cnossen MH, Nur E, Biemond BJ, Bartels M, et al. 2022. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study. Am J Hematol. 97(7):E226–E229.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, et al. 2019. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 381(6):509–519.
   PubMed Web of Science ®Google Scholar
• Vinjamur DS, Bauer DE, Orkin SH. 2018. Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. Br J Haematol. 180(5):630–643.
   PubMed Web of Science ®Google Scholar
• Vittorio S, Adornato I, Gitto R, Peña-Díaz S, Ventura S, De Luca L. 2020. Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease. J Enzyme Inhib Med Chem. 35(1):1727–1735.
   PubMed Web of Science ®Google Scholar
• Votano JR, Altman J, Wilchek M, Gorecki M, Rich A. 1984. Potential use of biaromatic l-phenylalanyl derivatives as therapeutic agents in the treatment of sickle cell disease. Proc Natl Acad Sci U S A. 81(10):3190–3194.
   PubMed Web of Science ®Google Scholar
• Votano JR, Gorecki M, Rich A. 1977. Sickle hemoglobin aggregation: a new class of inhibitors. Science. 196(4295):1216–1219.
   PubMed Web of Science ®Google Scholar
• Votano JR, Rich A. 1985. Inhibition of deoxyhemoglobin s polymerization by biaromatic peptides found to associate with the hemoglobin molecule at a preferred site. Biochemistry. 24(8):1966–1970.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ferrone FA. 2013. Dissecting the energies that stabilize sickle hemoglobin polymers. Biophys J. 105(9):2149–2156.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kishchenko G, Chen Y, Josephs R. 2000. Polymerization of deoxy-sickle cell hemoglobin in high-phosphate buffer. J Struct Biol. 131(3):197–209.
   PubMed Web of Science ®Google Scholar
• Widom B. 1982. Potential-distribution theory and the statistical mechanics of fluids. J Phys Chem. 86(6):869–872.
   Web of Science ®Google Scholar
• Williams TN. 2016. Sickle cell disease in sub-Saharan Africa. Hematol Oncol Clin North Am. 30(2):343–358.
   PubMed Web of Science ®Google Scholar
• Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, et al. 2011. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 108(10):4194–4199.
   PubMed Web of Science ®Google Scholar
• Wishner BC, Ward KB, Lattman EE, Love WE. 1975. Crystal structure of sickle-cell deoxyhemoglobin at 5 Å resolution. J Mol Biol. 98(1):179–194.
   PubMed Web of Science ®Google Scholar
• Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, et al. 2016. A de novo compound targeting α-synuclein improves deficits in models of Parkinson’s disease. Brain. 139(Pt 12):3217–3236.
   PubMedGoogle Scholar
• Xavier P, Galamba N. 2021. Effect of urea on the hydration and aggregation of hydrophobic and amphiphilic solute models: implications to protein aggregation. J Chem Phys. 155(14):144501.
   PubMed Web of Science ®Google Scholar
• Xu GG, Pagare PP, Ghatge MS, Safo RP, Gazi A, Chen Q, David T, Alabbas AB, Musayev FN, Venitz J, et al. 2017. Design, synthesis, and biological evaluation of ester and ether derivatives of antisickling agent 5-HMF for the treatment of sickle cell disease. Mol Pharm. 14(10):3499–3511.
   PubMed Web of Science ®Google Scholar
• Xu JZ, Conrey A, Frey I, Gwaabe E, Menapace LA, Tumburu L, Lundt M, Lequang T, Li Q, Glass K, et al. 2022. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood. 140(19):2053–2062.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yao Y, Zhou Y, Li X, Tang Y, Wei G. 2023. EGCG attenuates α-synuclein protofibril-membrane interactions and disrupts the protofibril. Int J Biol Macromol. 230:123194.
   PubMedGoogle Scholar
• Young LM, Ashcroft AE, Radford SE. 2017. Small molecule probes of protein aggregation. Curr Opin Chem Biol. 39:90–99.
   PubMed Web of Science ®Google Scholar
• Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, et al. 2004. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia: new α-synuclein gene mutation. Ann Neurol. 55(2):164–173.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu X, Ji M, Liu S, Wu X, Wang Y, Liu R. 2018. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson’s disease. Food Funct. 9(12):6414–6426.
   PubMed Web of Science ®Google Scholar
• Zhou L, Kurouski D. 2020. Structural characterization of individual α-synuclein oligomers formed at different ­stages of protein aggregation by atomic force microscopy-infrared spectroscopy. Anal Chem. 92(10):6806–6810.
   PubMed Web of Science ®Google Scholar
• Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. 2004. The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils. J Biol Chem. 279(26):26846–26857.
   PubMed Web of Science ®Google Scholar
• Zurlo E, Kumar P, Meisl G, Dear AJ, Mondal D, Claessens MMAE, Knowles TPJ, Huber M. 2021. In situ kinetic measurements of α-synuclein aggregation reveal large population of short-lived oligomers. PLOS One. 16(1):e0245548.
   PubMed Web of Science ®Google Scholar